Inhibitors of tace

ABSTRACT

The present invention relates to compounds that inhibit TACE, compositions thereof, and methods of using those compounds and compositions for treating diseases.

TECHNICAL FIELD OF THE INVENTION

The present invention relates to compounds that inhibit TACE,compositions thereof, and methods of using those compounds andcompositions for treating diseases.

BACKGROUND OF THE INVENTION

Adamalysin (“ADAM”) is a subfamily of enzymes in the zincmetalloendopeptidases. ADAMs contain a disintigrin domain in addition toa metalloproteinase-like domain. At least twenty-three distinct ADAMshave been identified thus far.

ADAM-17, also known as tumor necrosis factor-alpha converting enzyme(hereinafter “TACE”), is the most well known ADAM. TACE is responsiblefor cleavage of cell bound tumor necrosis factor-alpha (“TNF-α”). TNF-αis implicated in many infectious and autoimmune diseases. Moreover,TNF-α is the prime mediator in the inflammatory response seen in sepsisand septic shock. There are two types of TNF-α, a type II membraneprotein of relative molecular mass of 26 kD, and a soluble 17 kD formgenerated from the cell bound protein by specific proteolytic cleavage.The soluble 17 kD form of TNF-α is released by the cell and isassociated with the deleterious effects of TNF-α. This form of TNF-α isalso capable of acting at sites distant from the site of synthesis.Thus, inhibitors of TACE prevent the formation of soluble TNF-α and thusprevent the deleterious effects of the soluble factor.

Although a variety of TACE inhibitors are known in the art, many ofthese molecules are peptidic and peptide-like which suffer frombioavailability and pharmacokinetic problems. In addition, many of thesemolecules are non-selective, being potent inhibitors of matrixmetalloproteinases and, in particular, MMP-1. Inhibition of MMP-1(collagenase-1) has been postulated to cause joint pain in clinicaltrials of MMP inhibitors.

Thus, there is a need for TACE inhibitors that are selective, orallybioavailable, non-peptidic for the treatment of diseases associated withTNF-α.

SUMMARY OF THE INVENTION

The present invention relates to compounds of formula (I):

wherein:

ring A is an optionally substituted 4-7 membered heterocyclic ringcontaining up to 2 units of unsaturation and 0 to 3 ring heteroatoms inaddition to the nitrogen atom, wherein each heteroatom is independentlyselected from O, S, or NR_(x);

wherein ring A is optionally fused to aryl, cycloaliphatic, heteroaryl,or heterocyclic ring;

wherein two ring atoms in ring A are optionally bridged by 1-3 atoms toform a cycloaliphatic or heterocyclic ring, or wherein a ring atom inring A is optionally part of another ring to form a spiro ring, whereinsaid spiro ring is a cycloaliphatic or heterocyclyl;

R_(x) is H, aliphatic, OH, —C(O)—O-(cycloaliphatic or aliphatic or—C(O)-(cycloaliphatic or aliphatic);

Ar is an optionally substituted aryl or heteroaryl;

X is O, S, NR_(x), —CH═, —C≡, or CH₂;

R₁ is C2-C8 alkynyl, optionally substituted with up to 4 substituentsselected from halo, Ar, cycloaliphatic, heterocyclyl, NH₂,NH(cycloaliphatic or aliphatic), N(cycloaliphatic or aliphatic)₂,halogen, —OH, —O(cycloaliphatic or aliphatic), NO₂, —CN, —CO₂H,—CO₂(cycloaliphatic or aliphatic), —O(halo-cycloaliphatic or aliphatic),or halo-(cycloaliphatic or aliphatic); and

wherein up to 2 —CH₂— in said alkynyl, cycloaliphatic or aliphatic maybe replaced with O, S, or —NR_(x)—.

The present invention also relates to compositions thereof, and methodsof treating diseases using such compounds and compositions.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds having formula (I):

wherein:

ring A is an optionally substituted 4-7 membered heterocyclic ringcontaining up to 2 units of unsaturation and 0 to 3 ring heteroatoms inaddition to the nitrogen atom, wherein each heteroatom is independentlyselected from O, S, or NR_(x);

wherein ring A is optionally fused to aryl, cycloaliphatic, heteroaryl,or heterocyclic ring;

wherein two ring atoms in ring A are optionally bridged by 1-3 atoms toform a cycloaliphatic or heterocyclic ring, or wherein a ring atom inring A is optionally part of another ring to form a spiro ring, whereinsaid spiro ring is a cycloaliphatic or heterocyclyl;

R_(x) is H, aliphatic, OH, —C(O)—O-(cycloaliphatic or aliphatic or—C(O)-(cycloaliphatic or aliphatic);

Ar is an optionally substituted aryl or heteroaryl;

X is O, S, NR_(x), —CH═, —C≡, or CH₂;

R₁ is C2-C8 alkynyl, optionally substituted with up to 4 substituentsselected from halo, Ar, cycloaliphatic, heterocyclyl, NH₂,NH(cycloaliphatic or aliphatic), N(cycloaliphatic or aliphatic)₂,halogen, —OH, —O(cycloaliphatic or aliphatic), NO₂, —CN, —CO₂H,—CO₂(cycloaliphatic or aliphatic), —O(halo-cycloaliphatic or aliphatic),or halo-(cycloaliphatic or aliphatic); and

wherein up to 2 —CH₂— in said alkynyl, cycloaliphatic or aliphatic maybe replaced with O, S, or —NR_(x)—.

As used herein, the following definitions shall apply unless otherwiseindicated.

The phrase “optionally substituted” is used interchangeably with thephrase “substituted or unsubstituted.” Unless otherwise indicated, anoptionally substituted group may have a substituent at eachsubstitutable position of the group, and each substitution isindependent of the other.

The term “aliphatic” or “aliphatic group”, as used herein, means astraight-chain or branched, substituted or unsubstituted hydrocarbonchain that is completely saturated (alkyl) or is unsaturated (alkenyl oralkynyl). Unless otherwise specified, an aliphatic group has 1 to 12carbon atoms. Preferably, an aliphatic group has 1-6 carbon atoms. Up totwo —CH₂— in said aliphatic may be replaced with O, S, or —NR_(x)—.

The term “cycloaliphatic” means a 3-8 membered monocyclic hydrocarbonring or a 8-12 membered bicyclic hydrocarbon ring that is completelysaturated (e.g., cycloalkyl) or that contains one or more units ofunsaturation (e.g., cycloalkenyl), but which is not aromatic, and has asingle point of attachment to the rest of the molecule.

The term “heteroatom” unless otherwise specified means nitrogen, oxygen,or sulfur and includes any oxidized form of nitrogen and sulfur, and thequaternized form of any basic nitrogen. Also the term “nitrogen”includes a substitutable nitrogen of a heterocyclic ring. As an example,in a saturated or partially unsaturated ring having 0-3 heteroatomsselected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as inN-substituted pyrrolidinyl).

The term “unsaturated”, as used herein, means a double bond or a triplebond. Each such bond constitutes one unit of unsaturation.

The term “aryl” used alone or as part of a larger moiety as in“aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclicand tricyclic ring systems having a total of five to fourteen ringmembers, wherein at least one ring in the system is aromatic and whereineach ring in the system contains 3 to 7 ring members. The term “aryl”may be used interchangeably with the term “aryl ring”. Phenyl is anexample of aryl.

The term “heterocycle”, “heterocyclyl”, “heterocycloaliphatic”, or“heterocyclic” as used herein means non-aromatic, monocyclic, bicyclicor tricyclic ring systems having in total 5 to 14 ring members in whichone or more ring members is a heteroatom, wherein each ring in thesystem contains 3 to 7 ring members.

The term “heteroaryl”, used alone or as part of a larger moiety as in“heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclicand tricyclic ring systems, wherein at least one ring in the system isaromatic, at least one ring in the system contains one or moreheteroatoms. Unless otherwise specified, such ring systems have a totalof 5 to 15 ring members, wherein each ring in the system contains 3 to 7ring members. The term “heteroaryl” may be used interchangeably with theterm “heteroaryl ring” or the term “heteroaromatic”.

An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) orheteroaryl (including heteroaralkyl and heteroarylalkoxy and the like)group may contain one or more substituents. Suitable substituents on theunsaturated carbon atom of an aryl, heteroaryl, aralkyl, orheteroaralkyl group include halogen, —R^(o), —OR^(o), —SR^(o),1,2-methylene-dioxy, 1,2-ethylenedioxy, phenyl (Ph) optionallysubstituted with R^(o), —O(Ph) optionally substituted with R^(o),—CH₂(Ph) optionally substituted with R^(o), —CH₂CH₂(Ph), optionallysubstituted with R^(o), —NO₂, —CN, —N(R^(o))₂, —NR^(o)C(O)R^(o),—NR^(o)C(O)N(R^(o))₂, —NR^(o)CO₂R^(o), —NR^(o)NR^(o)C(O)R^(o),—NR^(o)NR^(o)C(O)N(R^(o))₂, —NR^(o)NR^(o)CO₂R^(o), —C(O)C(O)R^(o),—C(O)CH₂C(O)R^(o), —CO₂R^(o), —C(O)R^(o), —C(O)N(R^(o))₂,—OC(O)N(R^(o))₂, —S(O)₂R^(o), —SO₂N(R^(o))₂, —S(O)R^(o),—NR^(o)SO₂N(R^(o))₂, —NR^(o)SO₂R^(o), —C(═S)N(R^(o))₂,—C(═NH)—N(R^(o))₂, or —(CH₂)_(q)NHC(O)R^(o) wherein q is 0-2, andwherein each R^(o) is independently selected from hydrogen, optionallysubstituted C1-C6 aliphatic, an unsubstituted 5-6 membered heteroaryl orheterocyclic ring, phenyl, —O(Ph), or —CH₂(Ph), or wherein twooccurrences of R^(o), on the same substituent or different substituents,taken together, form a 5-8-membered heterocyclyl or heteroaryl ringhaving 1-3 heteroatoms independently selected from nitrogen, oxygen, orsulfur. Optional substituents on the aliphatic group of R^(o) areselected from NH₂, NH(C₁₋₄ aliphatic), N(C₁₋₄ aliphatic)₂, halogen, C₁₋₄aliphatic, OH, O(C₁₋₄ aliphatic), NO₂, CN, CO₂H, CO₂(C₁₋₄ aliphatic),O(halo C₁₋₄ aliphatic), or halo C₁₋₄ aliphatic.

An aliphatic group or a non-aromatic heterocyclic ring may contain oneor more substituents. Suitable substituents on the saturated carbon ofan aliphatic group or of a non-aromatic heterocyclic ring include thoselisted above for the unsaturated carbon of an aryl or heteroaryl groupand the following: ═O, ═S, ═NNHR*, ═NN(R*)₂, ═NNHC(O)R*, ═NNHCO₂(alkyl),═NNHSO₂(alkyl), or ═NR*, where each R* is independently selected fromhydrogen or an optionally substituted C₁₋₆ aliphatic. Optionalsubstituents on the aliphatic group of R⁺ are selected from NH₂, NH(C₁₋₄aliphatic), N(C₁₋₄ aliphatic)₂, halogen, C₁₋₄ aliphatic, OH, O(C₁₋₄aliphatic), NO₂, CN, CO₂H, CO₂(C₁₋₄ aliphatic), O(halo C₁₋₄ aliphatic),or halo(C₁₋₄ aliphatic).

Optional substituents on the nitrogen of a non-aromatic heterocyclicring include —R⁺, —N(R⁺)₂, —C(O)R⁺, —OR⁺, —CO₂R⁺, —C(O)C(O)R⁺,—C(O)CH₂C(O)R⁺, —SO₂R⁺, —SO₂N(R⁺)₂, —C(═S)N(R⁺)₂, —C(═NH)—N(R⁺)₂, or—NR⁺SO₂R⁺; wherein R⁺ is hydrogen, an optionally substituted C₁₋₆aliphatic, optionally substituted phenyl, optionally substituted —O(Ph),optionally substituted —CH₂(Ph), optionally substituted —CH₂CH₂(Ph), oran unsubstituted 5-6 membered heteroaryl or heterocyclic ring, orwherein two occurrences of R⁺, on the same substituent or differentsubstituents, taken together, form a 5-8-membered heterocyclyl orheteroaryl ring having 1-3 heteroatoms independently selected fromnitrogen, oxygen, or sulfur. Optional substituents on the aliphaticgroup or the phenyl ring of R⁺ are selected from NH₂, NH(C₁₋₄aliphatic)⁻, N(C₁₋₄ aliphatic)₂, halogen, C₁₋₄ aliphatic, OH, O(C₁₋₄aliphatic), NO₂, CN, CO₂H, CO₂(C₁₋₄ aliphatic), O(halo C₁₋₄ aliphatic),or halo(C₁₋₄ aliphatic).

The term “alkylidene chain” refers to a straight or branched carbonchain that may be fully saturated or have one or more units ofunsaturation and has two points of attachment to the rest of themolecule.

A combination of substituents or variables is permissible only if such acombination results in a stable or chemically feasible compound. Astable compound or chemically feasible compound is one that is notsubstantially altered when kept at a temperature of 40° C. or less, inthe absence of moisture or other chemically reactive conditions, for atleast a week.

It will be apparent to one skilled in the art that certain compounds ofthis invention may exist in tautomeric forms, all such tautomeric formsof the compounds being within the scope of the invention. Unlessotherwise stated, structures depicted herein are also meant to includeall stereochemical forms of the structure; i.e., the R and Sconfigurations for each asymmetric center. Therefore, singlestereochemical isomers as well as enantiomeric and diastereomericmixtures of the present compounds are within the scope of the invention.Unless otherwise stated, structures depicted herein are also meant toinclude compounds that differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructures except for the replacement of a hydrogen by a deuterium ortritium, or the replacement of a carbon by a ¹³C- or ¹⁴C-enriched carbonare within the scope of this invention. Such compounds are useful, forexample, as analytical tools or probes in biological assays.

According to a preferred embodiment, ring A is an optionally substituted4, 5, or 7 membered heterocyclic ring containing up to 2 units ofunsaturation and 0 to 3 ring heteroatoms in addition to the nitrogenatom, wherein each heteroatom is independently selected from O, S, orNR_(x).

According to a preferred embodiment, ring A is an optionally substituted4-membered heterocyclic ring containing up to 2 heteroatoms in additionto the nitrogen atom, wherein each heteroatom is independently selectedfrom O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted4-membered heterocyclic ring containing up to 1 heteroatoms in additionto the nitrogen atom, wherein each heteroatom is independently selectedfrom O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted4-membered heterocyclic ring containing up to 0 heteroatoms in additionto the nitrogen atom.

According to a preferred embodiment, ring A is a monosubstituted4-membered heterocyclic ring containing 0 heteroatoms in addition to thenitrogen atom.

According to a preferred embodiment, ring A is an unsubstituted4-membered heterocyclic ring containing 0 heteroatoms in addition to thenitrogen atom.

According to preferred embodiment, ring A is a 4-membered heterocyclicring containing 0 heteroatoms in addition to the nitrogen atom andwherein two ring atoms in ring A are optionally bridged by 1-3 atoms toform a cycloalkyl or heterocyclic ring, or wherein a ring atom in ring Ais optionally disubstituted to form a spiro ring, wherein said spiroring is a cycloalkyl or heterocyclyl.

According to another preferred embodiment, ring A is an optionallysubstituted 5-membered heterocyclic ring containing up to 2 heteroatomsin addition to the nitrogen atom, wherein each heteroatom isindependently selected from O, S, or NR_(x).

According to another preferred embodiment, ring A is an optionallysubstituted 5-membered heterocyclic ring having a unit of unsaturationand containing up to 2 heteroatoms in addition to the nitrogen atom,wherein each heteroatom is independently selected from O, S, or NR_(x).

According to another preferred embodiment, ring A is an optionallysubstituted 5-membered heterocyclic ring containing up to 2 heteroatomsin addition to the nitrogen atom, wherein each heteroatom isindependently selected from O, S, or NR_(x), and wherein said ring isfused to a cycloalkyl, heterocyclyl, or heteroaromatic.

According to another preferred embodiment, ring A is an optionallysubstituted 5-membered heterocyclic ring containing up to 1 heteroatomsin addition to the nitrogen atom, said heteroatom is O, S, or NR_(x).

According to another preferred embodiment, ring A is an optionallysubstituted 5-membered heterocyclic ring containing 1 heteroatoms inaddition to the nitrogen atom, wherein said heteroatom is O, S, orNR_(x).

According to another preferred embodiment, ring A is a monosubstituted5-membered heterocyclic ring containing 1 heteroatoms in addition to thenitrogen atom, wherein said heteroatom is O, S, or NR_(x). Preferably,said heteroatom is O.

According to another preferred embodiment, ring A is a monosubstituted5-membered heterocyclic ring containing 0 heteroatoms in addition to thenitrogen atom.

According to another preferred embodiment, ring A is an unsubstituted5-membered heterocyclic ring containing 0 heteroatoms in addition to thenitrogen atom.

According to preferred embodiment, ring A is a 5-membered heterocyclicring containing up to 3 heteroatoms in addition to the nitrogen atom andwherein two ring atoms in ring A are optionally bridged by 1-3 atoms toform a cycloalkyl or heterocyclic ring, or wherein a ring atom in ring Ais optionally disubstituted to form a spiro ring, wherein said spiroring is a cycloalkyl or heterocyclyl.

According to a preferred embodiment, ring A is an optionally substituted6-membered heterocyclic ring containing up to 2 units of unsaturationand 0 to 3 heteroatoms in addition to the nitrogen atom, wherein eachheteroatom is independently selected from O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted6-membered heterocyclic ring containing up to 1 units of unsaturationand 0 to 3 heteroatoms in addition to the nitrogen atom, wherein eachheteroatom is independently selected from O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted6-membered heterocyclic ring containing 0 to 3 heteroatoms in additionto the nitrogen atom, wherein each heteroatom is independently selectedfrom O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted6-membered heterocyclic ring containing up to 2 units of unsaturationand 1 to 3 heteroatoms in addition to the nitrogen atom, wherein eachheteroatom is independently selected from O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted6-membered heterocyclic ring containing up to 1 unit of unsaturation and1 to 3 heteroatoms in addition to the nitrogen atom, wherein eachheteroatom is independently selected from O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted6-membered heterocyclic ring containing 1 to 3 heteroatoms in additionto the nitrogen atom, wherein each heteroatom is independently selectedfrom O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted6-membered heterocyclic ring containing 1 to 2 heteroatoms in additionto the nitrogen atom, wherein each heteroatom is independently selectedfrom O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted6-membered heterocyclic ring containing 1 heteroatom in addition to thenitrogen atom, wherein each heteroatom is independently selected from O,S, or NR_(x).

According to a preferred embodiment, ring A is an monosubstituted6-membered heterocyclic ring containing 1 heteroatom in addition to thenitrogen atom, wherein said heteroatom is selected from O, S, or NR_(x).

According to a preferred embodiment, ring A is an unsubstituted6-membered heterocyclic ring containing 1 heteroatom in addition to thenitrogen atom, wherein said heteroatom is independently selected from O,S, or NR_(x).

According to a preferred embodiment, ring A is an unsubstituted6-membered heterocyclic ring containing 1 heteroatom in addition to thenitrogen atom, wherein said heteroatom is selected from O, S, or NR_(x).

According to preferred embodiment, ring A is a 6-membered heterocyclicring containing up to 3 heteroatoms in addition to the nitrogen atom andwherein two ring atoms in ring A are optionally bridged by 1-3 atoms toform a cycloalkyl or heterocyclic ring, or wherein a ring atom in ring Ais optionally disubstituted to form a spiro ring, wherein said spiroring is a cycloalkyl or heterocyclyl ring.

According to a preferred embodiment, ring A is an optionally substituted7-membered heterocyclic ring containing 0 to 3 heteroatoms in additionto the nitrogen atom, wherein each heteroatom is independently selectedfrom O, S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted7-membered heterocyclic ring containing 2 heteroatoms in addition to thenitrogen atom, wherein each heteroatom is independently selected from O,S, or NR_(x).

According to a preferred embodiment, ring A is an optionally substituted7-membered heterocyclic ring containing 1 heteroatom in addition to thenitrogen atom, wherein each heteroatom is independently selected from O,S, or NR_(x).

According to a preferred embodiment, ring A is a monosubstituted7-membered heterocyclic ring containing 1 heteroatom in addition to thenitrogen atom, wherein each heteroatom is independently selected from O,S, or NR_(x).

According to a preferred embodiment, ring A is a monosubstituted7-membered heterocyclic ring containing 0 heteroatoms in addition to thenitrogen atom.

According to a preferred embodiment, ring A is an unsubstituted7-membered heterocyclic ring containing 0 heteroatoms in addition to thenitrogen atom.

According to a preferred embodiment, ring A is a 7-membered heterocyclicring containing 0 to 3 heteroatoms in addition to the nitrogen atom,wherein each heteroatom is independently selected from O, S, or NR_(x),wherein two ring atoms in ring A are optionally bridged by 1-3 atoms toform a cycloalkyl or heterocyclic ring, or wherein a ring atom in ring Ais optionally disubstituted to form a spiro ring, wherein said spiroring is a cycloalkyl or heterocyclyl ring.

According to a preferred embodiment, the ring fused to ring A isselected from phenyl, triazinyl, pyrazinyl, pyrimidinyl, pyridazinyl,pyridinyl, thiadiazolyl, triazolyl, oxadiazolyl, isothiazolyl,pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyrrolyl, thiophenyl,furanyl, indolizinyl, indolyl, isoindolyl, benzofuranyl,benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl,purinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthazinyl,quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl,acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, indenyl, naphthyl,azulinyl, or anthracenyl or:

wherein R is aliphatic, aralkyl, heterocyclic, heterocyclylalkyl,heteroaryl, or heteroaralkyl.

According to another preferred embodiment, ring A, including thenitrogen atom attached to —S(O)₂— is pyrrolidinyl ring.

According to another preferred embodiment, ring A, including thenitrogen atom is:

According to another preferred embodiment ring A, including the nitrogenatom is:

According to another preferred embodiment, ring A, including thenitrogen atom is:

According to a preferred embodiment, ring A has up to threesubstituents. According to another preferred embodiment, ring A has upto two substituents. According to another preferred embodiment, ring Ahas up to one substituent. According to another preferred embodiment,ring A is unsubstituted.

Preferred substituents on ring A include aliphatic, cyano, halo,hydroxy, —NOH, carboxy, oxo, amido, cyanoaliphatic, hydroxyaliphatic,thioaliphatic, carboxyaliphatic, aliphatic-oxycarbonyl,aliphatic-carbonylaliphatic, aliphatic-cycloaliphatic,aliphatic-cycloaliphatic-aliphatic, aliphaticsulfonyl, aryl,aryl-aliphatic, aryl-aliphatic-oxyaliphatic,aryl(aliphatic-carbonyl)aliphatic, arylcarbamoylaliphatic,heterocyclylcarbamoylaliphatic, aliphatic-carbamoylaliphatic,cycloaliphatic-carbamoylaliphatic, diaryl-aliphatic,aryl(carboxyaliphatic)amide, arylamino, arylcarbonyl, arylsulfonyl,cycloaliphatic, cycloaliphatic-carbonyl, cycloaliphatic-alkyl,heteroaryl, heteroaryl-aliphatic, heterocyclyl, orheterocyclyl-aliphatic.

According to another preferred embodiment, ring A optionally comprisesup to 3 substituents, wherein:

the first of said substituents, if present, is selected from R^(X), R²,R⁴ or R⁵,

the second of said substituents, if present, is selected from R^(X) orR⁴, and

the third of said substituents, if present, is R^(X); wherein:

each R^(X) is independently selected from 1,2-methylenedioxy,1,2-ethylenedioxy, R⁶ or (CH₂)_(n)—Y;

wherein n is 0, 1 or 2; and

Y is selected from halogen, CN, NO₂, CF₃, OCF₃, OH, SR⁶, S(O)R⁶, SO₂R⁶,NH₂, NHR⁶, N(R⁶)₂, NR⁶R⁸, COOH, COOR⁶ or OR⁶;

each R² is independently selected from (C₁-C₆)-straight or branchedalkyl, or (C₂-C₆)-straight or branched alkenyl or alkynyl; and each R²optionally comprises up to 2 substituents, wherein:

the first of said substituents, if present, is selected from R^(X), R⁴and R⁵′ and

the second of said substituents, if present, is R^(X);

each R⁴ is independently selected from OR⁵, OC(O)R⁶, OC(O)R⁵, OC(O)OR⁶,OC(O)OR⁵, OC(O)N(R⁶)₂, OP(O) (OR⁶)₂, SR⁶, SR⁵, S(O)R⁶, S(O)R⁵, SO₂R⁶,SO₂R⁵, SO₂N(R⁶)₂, SO₂NR⁵R⁶. SO₃R⁶, C(O)R⁵, C(O)OR⁵, C(O)R⁶, C(O)OR⁶,NC(O)C(O)R⁶, NC(O)C(O)R⁵, NC(O)C(O)OR⁶, NC(O)C(O)N(R⁶)₂, C(O)N(R⁶)₂,C(O)N(OR⁶)R⁶, C(O)N(OR⁶)R⁵, C(NOR⁶)R⁶, C(NOR⁶)R⁵, N(R⁶)₂, NR⁶C(O)R¹,NR⁶C(O)R⁶, NR⁶C(O)R⁵, NR⁶C(O)OR⁶, NR⁶C(O)OR⁵, NR⁶C(O)N(R⁶)₂,NR⁶C(O)NR⁵R⁶, NR⁶SO₂R⁶, NR⁶SO₂R⁵, NR⁶SO₂N(R⁶)₂, NR⁶SO₂NR⁵R⁶, N(OR⁶)R⁶,N(OR⁶)R⁵, P(O)(OR⁶)N(R⁶)₂, and P(O)(OR⁶)₂;

each R⁵ is a cycloaliphatic, aryl, heterocyclyl, or heteroaromatic; andeach R⁵ optionally comprises up to 3 substituents, each of which, ifpresent, is R¹;

each R⁶ is independently selected from H, (C₁-C₆)-straight or branchedalkyl, or (C₂-C₆) straight or branched alkenyl; and each R⁶ optionallycomprises a substituent that is R⁷;

R⁷ is a cycloaliphatic, aryl, heterocyclyl, or heteroaromatic; and eachR⁷ optionally comprises up to 2 substituents independently chosen fromH, (C₁-C₆)-straight or branched alkyl, (C₂-C₆) straight or branchedalkenyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH₂)_(n)-Z;

wherein n is 0, 1 or 2; and

Z is selected from halogen, CN, NO₂, CF₃, OCF₃, OH, S(C₁-C₆)-alkyl,SO(C₁-C₆)-alkyl, SO₂(C₁-C₆)-alkyl, NH₂, NH(C₁-C₆)-alkyl,N((C₁-C₆)-alkyl)₂, N((C₁-C₆)-alkyl)R⁸, COOH, C(O)O(C₁-C₆)-alkyl orO(C₁-C₆)-alkyl; and

R⁸ is an amino protecting group.

The term “amino protecting group” refers to a suitable chemical groupthat may be attached to a nitrogen atom. The term “protected” refers towhen the designated functional group is attached to a suitable chemicalgroup (protecting group). Examples of suitable amino protecting groupsand protecting groups are described in T. W. Greene and P. G. M. Wuts,Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons(1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents forOrganic Synthesis, John Wiley and Sons (1994); L. Paquette, ed.Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons(1995) and are exemplified in certain of the specific compounds used inthis invention.

According to another preferred embodiment, R₁ is C2-C8 alkynyl,optionally substituted with up to 3 substituents selected from halo, Ar,cycloalkyl, heterocyclyl, heteroaromatic, NH₂, NH(C1-C4 aliphatic),N(C1-C4 aliphatic)₂, halogen, OH, O(C1-C4 aliphatic) NO₂, CN, CO₂H,CO₂(C1-C4 aliphatic), O(halo-C1-C4 aliphatic), or halo-C1-C4 aliphatic.

According to another embodiment, R₁ is C2-C8 alkynyl.

According to another preferred embodiment, R₁ is 2-butynyl.

According to another preferred embodiment, Ar is an optionallysubstituted monocyclic aryl ring or a monocyclic heteroaryl ring.

According to another preferred embodiment, Ar is an aromatic ring systemwith substituents that enhance the ability of said ring system to engagein a π-stacking interaction. Such substituents are well known to one ofskill in the art.

According to another preferred embodiment Ar is an optionallysubstituted phenyl or a 5-6 membered heteroaromatic ring.

According to another preferred embodiment, Ar is phenyl.

According to another preferred embodiment, Ar is triazinyl, pyrazinyl,pyrimidinyl, pyridazinyl, pyridinyl, thiadiazolyl, triazolyl,oxadiazolyl, isothiazolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl,pyrrolyl, thiophenyl, furanyl, indolizinyl, indolyl, isoindolyl,benzofuranyl, benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl,benzthiazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl,phthazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl,carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl,indenyl, naphthyl, azulinyl, or anthracenyl.

According to another preferred embodiment, Ar is triazinyl, pyrazinyl,pyrimidinyl, pyridazinyl, pyridinyl, thiadiazolyl, triazolyl,oxadiazolyl, isothiazolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl,pyrrolyl, thiophenyl or furanyl.

According to another preferred embodiment Ar is triazinyl, pyrazinyl,pyrimidinyl, pyridazinyl, or pyridinyl.

According to another preferred embodiment Ar is pyridinyl.

According to another preferred embodiment,

X is O, S, or NR_(x). According to another preferred embodiment X is—CH₂—. According to another preferred embodiment, X is O or S. Accordingto another preferred embodiment, X is O. According to another preferredembodiment, X is NH. According to another preferred embodiment, X isNR_(x).

According to another preferred embodiment, the present inventionprovides a compound of formula (I′):

wherein:

Y is O or CH₂;

one of X₁, X₂, X₃, and X₄ is ═CH—, and each of the other three of X₁,X₂, X₃, and X₄ is independently selected from ═N— or ═CH—;

X′ is selected from O or NR_(x);

R_(x) is H, aliphatic, OH, —C(O)—O-(cycloaliphatic or aliphatic or—C(O)-(cycloaliphatic or aliphatic);

R₁ is C2-C8 alkynyl, optionally substituted with up to 4 substituentsselected from halo, aryl, heteroaryl, cycloaliphatic, heterocyclyl, NH₂,NH(cycloaliphatic or aliphatic), N(cycloaliphatic or aliphatic)₂,halogen, —OH, —O(cycloaliphatic or aliphatic), NO₂, —CN, —CO₂H,—CO₂(cycloaliphatic or aliphatic), —O(halo-cycloaliphatic or aliphatic),or halo-(cycloaliphatic or aliphatic); and

wherein up to 2 —CH₂— in said alkynyl, cycloaliphatic or aliphatic maybe replaced with O, S, or —NR_(x)—.

Preferred compounds of formula (I) are as follows:

According to another preferred embodiment, the present inventionprovides a compound of formula 1 or 1B:

According to another preferred embodiment, the present inventionprovides compounds selected from Table 1 below:

TABLE 1 Compd. No. Structure 2

3

4

5

6

7

8

According to another embodiment, the present invention providescompounds of formula (II):

wherein:

ring A is an optionally substituted 4-7 membered cycloaliphatic ringhaving up to 2 units of unsaturation; or

ring A is an optionally substituted 4-7 membered heterocyclic ringhaving up to 2 units of unsaturation, wherein 1-3 ring atoms in ring Aother than the carbon atom attached to the S(O)₂ group is selected fromO, S, or NR_(x);

wherein ring A is optionally fused to aryl, cycloaliphatic, heteroaryl,or heterocyclic ring;

wherein two ring atoms in ring A are optionally bridged by 1-3 atoms toform a cycloaliphatic or heterocyclic ring, or wherein a ring atom inring A is optionally part of another ring to form a spiro ring, whereinsaid spiro ring is a cycloaliphatic or heterocyclyl;

R_(x) is H, aliphatic, OH, —C(O)—O-(cycloaliphatic or aliphatic or—C(O)-(aliphatic or aliphatic);

Ar is an optionally substituted aryl or heteroaryl;

X is O, S, NR_(x), —CH═, —C≡, or CH₂;

R₁ is C2-C8 alkynyl, optionally substituted with up to 3 substituentsselected from halo, Ar, cycloaliphatic, heterocyclyl, NH₂,NH(cycloaliphatic or aliphatic), N(cycloaliphatic or aliphatic)₂,halogen, —OH, —O(cycloaliphatic or aliphatic), NO₂, —CN, —CO₂H,—CO₂(cycloaliphatic or aliphatic), —O(halo-cycloaliphatic or aliphatic),or halo-(cycloaliphatic or aliphatic); and

wherein up to 2 —CH₂— in said alkynyl, cycloaliphatic or aliphatic maybe replaced with O, S, or —NR_(x)—.

According to a preferred embodiment, ring A in compounds of formula (II)is a 5-7 membered optionally substituted cycloaliphatic ring having upto 2 units of unsaturation.

According to a preferred embodiment, ring A in compounds of formula (II)is an optionally substituted cyclobutyl, cyclopentyl or cyclohexyl.

According to another preferred embodiment, ring A in compounds offormula (II) is cyclobutyl.

According to another preferred embodiment, ring A in compounds offormula (II) is cyclopentyl.

According to another preferred embodiment, ring A in compounds offormula (II) is cyclohexyl.

According to another preferred embodiment, ring A in compounds offormula (II) is an optionally substituted 4-7 membered heterocyclic ringhaving up to 2 units of unsaturation, wherein 1-3 ring atoms in ring Aother than the carbon atom attached to the S(O)₂ group is selected fromO, S, or NR_(x).

The preferred embodiments for radicals X, Ar, and R₁, and substituentsthereon in compounds of formula (I) are the same as those for compoundsof formula (I).

According to another preferred embodiment, ring A in formula (I) andformula (II), including the thio group, nitrogen atom, and the sulfonylgroup is selected from:

According to another preferred embodiment, ring A in formula (I) andformula (II), including the thio group, nitrogen atom, and the sulfonylgroup is selected from:

wherein R is as defined above.

According to another embodiment, the present invention providescompounds of formula (III):

wherein:

n is 0-4;

R_(x) is H, aliphatic, OH, —C(O)—O-(cycloaliphatic or aliphatic or—C(O)-(aliphatic or aliphatic);

Ar is an optionally substituted aryl or heteroaryl;

X is O, S, NR_(x), —CH═, —C≡, or CH₂;

R₁ is C2-C8 alkynyl, optionally substituted with up to 3 substituentsselected from halo, Ar, cycloaliphatic, heterocyclyl, NH₂,NH(cycloaliphatic or aliphatic), N(cycloaliphatic or aliphatic)₂,halogen, —OH, —O(cycloaliphatic or aliphatic), NO₂, —CN, —CO₂H,—CO₂(cycloaliphatic or aliphatic), —O(halo-cycloaliphatic or aliphatic),or halo-(cycloaliphatic or aliphatic); and

wherein up to 2 —CH₂— in said alkynyl, cycloaliphatic or aliphatic maybe replaced with O, S, or —NR_(x)—.

According to a preferred embodiment, n is 1-3.

According to another preferred embodiment, n is 2.

According to another preferred embodiment, n is 1.

Preferred embodiments of Ar, X, and R₁ and substituents thereon incompounds of formula (III) are the same as those for compounds offormula (I).

The scope of the present invention includes within its scopepharmaceutically acceptable prodrugs of the compounds of the presentinvention. A “pharmaceutically acceptable prodrug” means anypharmaceutically acceptable salt, ester, salt of an ester, or otherderivative of a compound of the present invention which, uponadministration to a recipient, is capable of providing (directly orindirectly) a compound of this invention or an active metabolite orresidue thereof. Preferred prodrugs are those that increase thebioavailability of the compounds of this invention when such compoundsare administered to a mammal or which enhance delivery of the parentcompound to a biological compartment (e.g., the brain or lymphaticsystem) relative to the parent species.

The compounds of the present invention may be readily prepared usingmethods known in the art. One such synthetic route is illustrated belowin Scheme 1, wherein radical Ar is illustrated with phenyl, and ring Ais illustrated with pyrrolidinyl. One of skill in the art will recognizethat this synthetic route can be readily exploited for other embodimentsof formula (I).

One of skill in the art will be well aware of analogous methods forpreparing compounds of formula (II) and formula (III).

The term “pharmaceutically acceptable carrier, adjuvant, or vehicle”refers to a non-toxic carrier, adjuvant, or vehicle that does notdestroy the pharmacological activity of the compound with which it isformulated. Pharmaceutically acceptable carriers, adjuvants or vehiclesthat may be used in the compositions of this invention include, but arenot limited to, ion exchangers, alumina, aluminum stearate, lecithin,serum proteins, such as human serum albumin, buffer substances such asphosphates, glycine, sorbic acid, potassium sorbate, partial glyceridemixtures of saturated vegetable fatty acids, water, salts orelectrolytes, such as protamine sulfate, disodium hydrogen phosphate,potassium hydrogen phosphate, sodium chloride, zinc salts, colloidalsilica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-basedsubstances, polyethylene glycol, sodium carboxymethylcellulose,polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers,polyethylene glycol and wool fat.

Pharmaceutically acceptable salts of the compounds of this inventioninclude those derived from pharmaceutically acceptable inorganic andorganic acids and bases. Examples of suitable acid salts includeacetate, adipate, alginate, aspartate, benzoate, benzenesulfonate,bisulfate, butyrate, citrate, camphorate, camphorsulfonate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,formate, fumarate, glucoheptanoate, glycerophosphate, glycolate,hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide,hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate,palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, salicylate, succinate, sulfate, tartrate,thiocyanate, tosylate and undecanoate. Other acids, such as oxalic,while not in themselves pharmaceutically acceptable, may be employed inthe preparation of salts useful as intermediates in obtaining thecompounds of the invention and their pharmaceutically acceptable acidaddition salts.

Salts derived from appropriate bases include alkali metal (e.g., sodiumand potassium), alkaline earth metal (e.g., magnesium), ammonium and N⁺(C₁₋₄ alkyl)₄ salts. This invention also envisions the quaternization ofany basic nitrogen-containing groups of the compounds disclosed herein.Water or oil-soluble or dispersible products may be obtained by suchquaternization.

The compositions of the present invention may be administered orally,parenterally, by inhalation spray, topically, rectally, nasally,buccally, vaginally or via an implanted reservoir. The term “parenteral”as used herein includes subcutaneous, intravenous, intramuscular,intra-articular, intra-synovial, intrasternal, intrathecal,intrahepatic, intralesional and intracranial injection or infusiontechniques. Preferably, the compositions are administered orally,intraperitoneally or intravenously. Sterile injectable forms of thecompositions of this invention may be aqueous or oleaginous suspension.These suspensions may be formulated according to techniques known in theart using suitable dispersing or wetting agents and suspending agents.The sterile injectable preparation may also be a sterile injectablesolution or suspension in a non-toxic parenterally-acceptable diluent orsolvent, for example as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that may be employed are water,Ringer's solution and isotonic sodium chloride solution. In addition,sterile, fixed oils are conventionally employed as a solvent orsuspending medium.

For this purpose, any bland fixed oil may be employed includingsynthetic mono- or di-glycerides. Fatty acids, such as oleic acid andits glyceride derivatives are useful in the preparation of injectables,as are natural pharmaceutically-acceptable oils, such as olive oil orcastor oil, especially in their polyoxyethylated versions. These oilsolutions or suspensions may also contain a long-chain alcohol diluentor dispersant, such as carboxymethyl cellulose or similar dispersingagents that are commonly used in the formulation of pharmaceuticallyacceptable dosage forms including emulsions and suspensions. Othercommonly used surfactants, such as Tweens, Spans and other emulsifyingagents or bioavailability enhancers which are commonly used in themanufacture of pharmaceutically acceptable solid, liquid, or otherdosage forms may also be used for the purposes of formulation.

The pharmaceutically acceptable compositions of this invention may beorally administered in any orally acceptable dosage form including, butnot limited to, capsules, tablets, aqueous suspensions or solutions. Inthe case of tablets for oral use, carriers commonly used include lactoseand corn starch. Lubricating agents, such as magnesium stearate, arealso typically added. For oral administration in a capsule form, usefuldiluents include lactose and dried cornstarch. When aqueous suspensionsare required for oral use, the active ingredient is combined withemulsifying and suspending agents. If desired, certain sweetening,flavoring or coloring agents may also be added.

Alternatively, the pharmaceutically acceptable compositions of thisinvention may be administered in the form of suppositories for rectaladministration. These can be prepared by mixing the agent with asuitable non-irritating excipient that is solid at room temperature butliquid at rectal temperature and therefore will melt in the rectum torelease the drug. Such materials include cocoa butter, beeswax andpolyethylene glycols.

The pharmaceutically acceptable compositions of this invention may alsobe administered topically, especially when the target of treatmentincludes areas or organs readily accessible by topical application,including diseases of the eye, the skin, or the lower intestinal tract.Suitable topical formulations are readily prepared for each of theseareas or organs.

Topical application for the lower intestinal tract can be effected in arectal suppository formulation (see above) or in a suitable enemaformulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutically acceptable compositionsmay be formulated in a suitable ointment containing the active componentsuspended or dissolved in one or more carriers. Carriers for topicaladministration of the compounds of this invention include, but are notlimited to, mineral oil, liquid petrolatum, white petrolatum, propyleneglycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax andwater. Alternatively, the pharmaceutically acceptable compositions canbe formulated in a suitable lotion or cream containing the activecomponents suspended or dissolved in one or more pharmaceuticallyacceptable carriers. Suitable carriers include, but are not limited to,mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax,cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutically acceptable compositions may beformulated as micronized suspensions in isotonic, pH adjusted sterilesaline, or, preferably, as solutions in isotonic, pH adjusted sterilesaline, either with or without a preservative such as benzylalkoniumchloride. Alternatively, for ophthalmic uses, the pharmaceuticallyacceptable compositions may be formulated in an ointment such aspetrolatum.

The pharmaceutically acceptable compositions of this invention may alsobe administered by nasal aerosol or inhalation. Such compositions areprepared according to techniques well-known in the art of pharmaceuticalformulation and may be prepared as solutions in saline, employing benzylalcohol or other suitable preservatives, absorption promoters to enhancebioavailability, fluorocarbons, and/or other conventional solubilizingor dispersing agents.

Most preferably, the pharmaceutically acceptable compositions of thisinvention are formulated for oral administration.

The amount of the compounds of the present invention that may becombined with the carrier materials to produce a composition in a singledosage form will vary depending upon the host treated, the particularmode of administration. Preferably, the compositions should beformulated so that a dosage of between 0.01-100 mg/kg body weight/day ofthe inhibitor can be administered to a patient receiving thesecompositions.

It should also be understood that a specific dosage and treatmentregimen for any particular patient will depend upon a variety offactors, including the activity of the specific compound employed, theage, body weight, general health, sex, diet, time of administration,rate of excretion, drug combination, and the judgment of the treatingphysician and the severity of the particular disease being treated. Theamount of a compound of the present invention in the composition willalso depend upon the particular compound in the composition.

Depending upon the particular condition, or disease, to be treated orprevented, additional therapeutic agents, which are normallyadministered to treat or prevent that condition, may also be present inthe compositions of this invention. As used herein, additionaltherapeutic agents that are normally administered to treat or prevent aparticular disease, or condition, are known as “appropriate for thedisease, or condition, being treated.”

According to another embodiment, the present invention provides a methodof inhibiting the in vivo cellular production/release of TNF-α in amammal, preferably human, comprising the step administering to saidmammal a composition of the present invention.

According to another embodiment, the present invention provides a methodof treating a TACE mediated disease in a mammal, including human,comprising the step of treating said mammal a composition according tothe present invention.

According to another embodiment, the present invention provides a methodof treating a disease selected from arthritis, inflammation,inflammatory bowel disease, Crohn's disease, emphysema, acuterespiratory distress syndrome, asthma, chronic obstructive pulmonarydisease, Alzheimer's disease, organ transplant toxicity, cachexia,allergic reactions, allergic contact hypersensitivity, cancer, tissueulceration, restenosis, periodontal disease, epidermolysis bullosa,osteoporosis, loosening of artificial joint implants, atherosclerosis,aortic aneurysm, congestive heart failure, myocardial infarction,stroke, cerebral ischemia, head trauma, spinal cord injury,endometriosis, general allergy, neuro-degenerative disorders, autoimmunedisorders, Huntington's disease, Parkinson's disease, migraine,depression, meningitis, neuropathic pain, cerebral amyloid angiopathy,nootropic or cognition enhancement, amyotrophic lateral sclerosis,multiple sclerosis, ocular angiogenesis, corneal injury, maculardegeneration, abnormal wound healing, burns, diabetes, tumor invasion,tumor growth, tumor metastasis, corneal scarring, scleritis, AIDS,sepsis, and septic shock in a mammal, including human, comprising thestep of administering to said mammal a composition of the presentinvention.

According to another embodiment, the present invention provides a methodof inhibiting the cleavage Of TNF-α from cell membranes in a mammal,comprising the step of administering to said mammal a compound of thepresent invention.

According to another embodiment, the present invention provides a methodof inhibiting TACE, comprising the step of contacting said TACE with acompound of the present invention.

In order that the invention described herein may be more fullyunderstood, the following examples are set forth. It should beunderstood that these examples are for illustrative purposes only andare not to be construed as limiting this invention in any manner.

EXAMPLES Example 1

Compound 1 was synthesized according to the following synthetic scheme:

I. 4-But-2-ynyloxy-N-[(R)-3-hydroxypyrrolidinyl]benzenesulfonamide (B)

4-But-2-ynyloxy-benzenesulfonyl chloride¹ A (0.3 g, 1.23 mmol) was addedto a stirred solution of (R)-pyrrolidinol (0.132 g, 1.51 mmol), andtriethylamine (0.4 mL) in THF (8 mL) and water (2 mL) at roomtemperature. The resulting mixture was stirred at room temperature for16 h. The reaction was then diluted with ethyl acetate (50 mL) andwashed with 10% HCl (10 mL) and water (25 mL). The organic layer wasdried (Na₂SO₄), filtered and concentrated under reduced pressure toprovide sulfonamide B (0.32 g, 89%) as a white solid.; ¹H NMR (CDCl₃,500 MHz) δ 7.85 (d, 2H), 7.07 (d, 2H), 4.71 (q, 2H), 4.39 (m, 1H),3.35-3.41 (m, 3H), 3.24 (m, 1H), 1.94 (m, 1H), 1.87 (t, 3H), 1.84-1.86(m, 1H), 1.60 (m, 1H); Mass Spec. FIA MS 296 (M+1), LCMS 296 (M+1), LCMSretention time 2.5 min (10%-90% CH₃CN/H₂O).

4-But-2-ynyloxy-N—[(R)-3-mercaptopyrrolidinyl]benzenesulfonamide (1)

Diethyl azodicarboxylate (0.29 mL, 1.83 mmol) was added to stirredsolution of B (0.27 g, 0.92 mmol), triphenylphosphine (0.48 g, 1.83mmol) in THF (10 mL) at 0° C. The resulting yellow solution was stirredat 0° C. for 5 min and thioacetic acid (0.13 mL, 1.83 mmol) was added.The resulting solution was stirred at room temperature for 30 min. anddiluted with ethyl acetate (50 mL) water (2×25 mL). The organic layerwas dried (Na₂SO₄) and concentrated under reduced pressure to afford anoil, which was purified by flash chromatography on silica gel elutingwith ethyl acetate/hexane in a gradient from (1:10) to (1:4) to provideC (0.31 g, 95.6%) as a white solid; Mass Spec. FIA MS 354 (M+1). A freshsolution of 10% sodium methoxide in methanol (2 mL ) was added to astirred solution of compound C (0.3 g, 0.85 mmol) in methanol (7 mL) andethyl acetate (3 mL) and stirred at room temperature for 10 min. Thereaction mixture was acidified with 10% HCl (25 mL) and extracted withethyl acetate (3×25 mL). The organic layers were dried (Na₂SO₄),filtered and concentrated under reduced pressure. The crude product waspurified by flash chromatography on silica gel eluting with ethylacetate/hexane (1:4) to provide 1 (0.206 g, 78%) as a white solid.; ¹HNMR (CDCl₃, 500 MHz) δ 7.90 (d, 2H), 7.07 (d, 2H), 4.72 (q, 2H), 3.67(dd, 1H), 3.25-3.41 (m, 3H), 3.06 (dd, 1H), 2.24 (m, 1H), 1.87 (t, 3H),1.71 (m, 1H), 1.57 (d, 1H); Mass Spec. FIA MS 312 (M+1), LCMS 312 (M+1),LCMS retention time 3.4 min. (10%-90% CH₃CN/H₂O).

Example 2

The compounds of this invention were tested for TACE inhibition usingthe method of A. J. H. Gearing et al., (1994) Nature 370, 555; and K. M.Mohler et al., (1994) Nature 370, 218. This continuous assay usesfluorescence resonance energy transfer (FRET). TACE catalyzed cleavageof the substrate peptide liberates the fluoropore from the proximity ofthe adjacent quenching moiety, and an increase in fluorescence signalresults.

Compound 1 was titrated in a 96 well format.

Assay: 10 mM HEPES, pH 7.5; 5 μM substrate (Bachem M-2155); 10 nM -20 nMTACE protein; 2% v/v DMSO. Fluorescence measured continuously; K_(i)values were determined by nonlinear regression analysis. Compound 1 hada K_(i) of 29 nM.

1. A compound having formula:

wherein: ring A is an optionally substituted membered heterocyclic ring;R_(x) is H, aliphatic, OH, —C(O)—O-(cycloaliphatic or aliphatic or—C(O)-(cycloaliphatic or aliphatic); Ar is an optionally substitutedaryl or heteroaryl; X is O, S, NR_(x), —CH═, —C≡, or CH₂; R₁ is C2-C8alkynyl, optionally substituted with up to 4 substituents selected fromhalo, Ar, cycloaliphatic, heterocyclyl, NH₂, NH(cycloaliphatic oraliphatic), N(cycloaliphatic or aliphatic)₂, halogen, —OH,—O(cycloaliphatic or aliphatic), NO₂, —CN, —CO₂H, —CO₂(cycloaliphatic oraliphatic), —O(halo-cycloaliphatic or aliphatic), orhalo-(cycloaliphatic or aliphatic); and wherein up to 2 —CH₂— in saidalkynyl, cycloaliphatic or aliphatic may be replaced with O, S, or—NR_(x)—. 2-11. (canceled)
 12. The compound according to claim 1,wherein ring A, including the nitrogen atom is:


13. The compound according to claim 1, wherein ring A optionallycomprises up to 3 substituents, wherein: the first of said substituents,if present, is selected from R^(X), R², R⁴ or R⁵, the second of saidsubstituents, if present, is selected from R^(X) or R⁴, and the third ofsaid substituents, if present, is R^(X); wherein: each R^(X) isindependently selected from 1,2-methylenedioxy, 1,2-ethylenedioxy, R⁶ or(CH₂)_(n)—Y; wherein n is 0, 1 or 2; and Y is selected from halogen, CN,NO₂, CF₃, OCF₃, OH, SR⁶, S(O)R⁶, SO₂R⁶, NH₂, NHR⁶, N(R⁶)₂, NR⁶R⁸, COOH,COOR⁶ or OR⁶; each R² is independently selected from (C₁-C₆)-straight orbranched alkyl, or (C₂-C₆)-straight or branched alkenyl or alkynyl; andeach R² optionally comprises up to 2 substituents, wherein: the first ofsaid substituents, if present, is selected from R^(X), R⁴ and R⁵, andthe second of said substituents, if present, is R^(X); each R⁴ isindependently selected from OR⁵, OC(O)R⁶, OC(O)R⁵, OC(O)OR⁶, OC(O)OR⁵,OC(O)N(R⁶)₂, OP(O)(OR⁶)₂, SR⁶, SR⁵, S(O)R⁶, S(O)R⁵, SO₂R⁶, SO₂R⁵,SO₂N(R⁶)₂, SO₂NR⁵R⁶, SO₃R⁶, C(O)R⁵, C(O)OR⁵, C(O)R⁶, C(O)OR⁶,NC(O)C(O)R⁶, NC(O)C(O)R⁵, NC(O)C(O)OR⁶, NC(O)C(O)N(R⁶)₂, C(O)N(R⁶)₂,C(O)N(OR⁶)R⁶, C(O)N(OR⁶)R⁵, C(NOR⁶)R⁶, C(NOR⁶)R⁵, N(R⁶)₂, NR⁶C(O)R¹,NR⁶C(O)R⁶, NR⁶C(O)R⁵, NR⁶C(O)OR⁶, NR⁶C(O)OR⁵, NR⁶C(O)N(R⁶)₂,NR⁶C(O)NR⁵R⁶, NR⁶SO₂R⁶, NR⁶SO₂R⁵, NR⁶SO₂N(R⁶)₂, NR⁶SO₂NR⁵R⁶, N(OR⁶)R⁶,N(OR⁶)R⁵, P(O)(OR⁶)N(R⁶)₂, and P(O)(OR⁶)₂; each R⁵ is a cycloaliphatic,aryl, heterocyclyl, or heteroaromatic; and each R⁵ optionally comprisesup to 3 substituents, each of which, if present, is R¹; each R⁶ isindependently selected from H, (C₁-C₆)-straight or branched alkyl, or(C₂-C₆) straight or branched alkenyl; and each R⁶ optionally comprises asubstituent that is R⁷; R⁷ is a cycloaliphatic, aryl, heterocyclyl, orheteroaromatic; and each R⁷ optionally comprises up to 2 substituentsindependently chosen from H, (C₁-C₆)-straight or branched alkyl, (C₂-C₆)straight or branched alkenyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or(CH₂)_(n)-Z; wherein n is 0, 1 or 2; and Z is selected from halogen, CN,NO₂, CF₃, OCF₃, OH, S(C₁-C₆)-alkyl, SO(C₁-C₆)-alkyl, SO₂(C₁-C₆)-alkyl,NH₂, NH(C₁-C₆)-alkyl, N((C₁-C₆)-alkyl)₂, N((C₁-C₆)-alkyl)R⁸, COOH,C(O)O(C₁-C₆)-alkyl or O(C₁-C₆)-alkyl; and R⁸ is an amino protectinggroup. 14-15. (canceled)
 16. The compound according to claim 1, whereinR₁ is C2-C8 alkynyl.
 17. The compound according to claim 16, wherein R₁is 2-butynyl.
 18. The compound according to claim 1, wherein Ar is anoptionally substituted monocyclic aryl ring or a monocyclic heteroarylring. 19-20. (canceled)
 21. The compound according to claim 18, whereinAr is phenyl.
 22. (canceled)
 23. The compound according to claim 18,wherein Ar is triazinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyridinyl,thiadiazolyl, triazolyl, oxadiazolyl, isothiazolyl, pyrazolyl,imidazolyl, thiazolyl, oxazolyl, pyrrolyl, thiophenyl or furanyl. 24.The compound according to claim 23, wherein Ar is pyridinyl. 25.(canceled)
 26. A compound having formula (I′):

wherein: Y is CH₂; one of X₁, X₂, X₃, and X₄ is ═CH—, and each of theother three of X₁, X₂, X₃, and X₄ is independently selected from ═N— or═CH—; X′ is selected from O or NR_(x); R_(x) is H, aliphatic, OH,—C(O)—O-(cycloaliphatic or aliphatic or —C(O)-(cycloaliphatic oraliphatic); R₁ is C2-C8 alkynyl, optionally substituted with up to 4substituents selected from halo, aryl, heteroaryl, cycloaliphatic,heterocyclyl, NH₂, NH(cycloaliphatic or aliphatic), N(cycloaliphatic oraliphatic)₂, halogen, —OH, —O(cycloaliphatic or aliphatic), NO₂, —CN,—CO₂H, —CO₂(cycloaliphatic or aliphatic), —O(halo-cycloaliphatic oraliphatic), or halo-(cycloaliphatic or aliphatic); and wherein up to 2CH₂— in said alkynyl, cycloaliphatic or aliphatic may be replaced withO, S, or —NR_(x)—.
 27. The compound according to claim 26, wherein saidcompound has formula:


28. The compound according to claim 26, wherein said compound hasformula:


29. The compound according to claim 26, wherein said compound isselected from: Compd. No. Structure 2

3

4

5

6

7

30-33. (canceled)
 34. The compound according to claim 1, wherein ring Ain formula (I) together with the sulfonyl group attached thereto isselected from:

wherein R is hydrogen. 35-38. (canceled)
 39. A pharmaceuticalcomposition comprising a compound according to claim 1 or claim 26, anda pharmaceutical carrier.
 40. A method of inhibiting TACE comprising thestep of contacting said TACE with a compound according to claim
 1. 41. Amethod of inhibiting the in vivo cellular production or release of TNF-αin a mammal, comprising the step administering to said mammal acomposition according to claim
 39. 42. A method of treating a TACEmediated disease in a mammal comprising the step of treating said mammala composition according to claim
 39. 43. A method of treating a diseaseselected from arthritis, inflammation, inflammatory bowel disease,Crohn's disease, emphysema, acute respiratory distress syndrome, asthma,chronic obstructive pulmonary disease, Alzheimer's disease, organtransplant toxicity, cachexia, allergic reactions, allergic contacthypersensitivity, cancer, tissue ulceration, restenosis, periodontaldisease, epidermolysis bullosa, osteoporosis, loosening of artificialjoint implants, atherosclerosis, aortic aneurysm, congestive heartfailure, myocardial infarction, stroke, cerebral ischemia, head trauma,spinal cord injury, endometriosis, general allergy, neuro-degenerativedisorders, autoimmune disorders, Huntington's disease, Parkinson'sdisease, migraine, depression, meningitis, neuropathic pain, cerebralamyloid angiopathy, nootropic or cognition enhancement, amyotrophiclateral sclerosis, multiple sclerosis, ocular angiogenesis, cornealinjury, macular degeneration, abnormal wound healing, burns, diabetes,tumor invasion, tumor growth, tumor metastasis, corneal scarring,scleritis, AIDS, sepsis, and septic shock in a mammal, including human,comprising the step of administering to said mammal a compositionaccording to claim
 39. 44. A method of inhibiting the cleavage of TNF-αfrom cell membranes in a mammal, comprising the step of administering tosaid mammal a compound according to claim 1.